With a legacy spanning 75 years, FAMAR has firmly established itself as a leading European Contract Development and Manufacturing Organization (CDMO) for pharmaceutical and cosmetic products.
Ahead of CDMO Live, FAMAR explain their strategic plans for growth and commitment to sustainability.
FAMAR offers an extensive range of CDMO services, including drug development, production, packaging, storage, and distribution. Additionally, FAMAR provides comprehensive services for regulatory affairs, covering strategic planning, market access, and drafting of technical and scientific specifications.
With over 1,800 employees, the company operates six Production Units and two Research and Development units for pharmaceutical products, medical devices and healthcare products in Greece, Italy, and Spain. FAMAR currently supplies 1.700 different products to more than 80 international markets.
FAMAR specializes in the manufacturing of all dosage forms, along with packaging and distribution, supported by a state-of-the-art logistics center. It offers a wide range of additional services, encompassing drug development from preclinical to clinical stages, providing regulatory support.
Despite recent worldwide challenges, FAMAR continues to enhance its position, driven by a relentless commitment to continuous improvement and strategic growth.
As a reliable CDMO, FAMAR is best known for its industrial deliverables to clients, namely Best in Class OTIF and all Quality metrics. Other additional most wanted services are provided to the markets as a result of the time and resources invested in the research of industry trends and needs.
Being the first CSCO of the market (Contract Services and Consulting Organization) through the new scheme of COMPASS by FAMAR proved to be the step up that our current and future clients are asking for. An organization that cannot only advise and consult on the different aspects that influence pharmaceutical activities, from incipient start-ups to well established blue chip Pharma companies, but that can also act and serve hands-on in the same way as it has been serving all its clients for the past 75 years.
This success is only possible to be achieved in a customer centric organizations such as FAMAR, where people are encouraged to think, anticipate and solve the needs and problems of their clients. Our experts always think “out-of-the-box” and our laboratories and dedicated R&D teams work on forward-looking solutions for our clients. The development of knowledge through strong partnerships with Academia and specialized experts is conducted with the aim to be put at the service of our clients and their ever more demanding needs. Our clients are the focus of everything we do and with them we exchange ideas and collaborate on projects and initiatives with mutual benefit.
Strategic Growth
FAMAR’s robust growth reflects the company’s strategic investment in high-value projects and efficient operational practices.
The company’s investment strategy emphasizes continuous improvement and innovation. Recent initiatives, such as the investment in a state-of-the-art sterile production unit at the Avlonas site, demonstrate FAMAR’s dedication to expand its capabilities. This facility will enhance the company’s ability to produce injectable drugs, ensuring that FAMAR meets both current and future market demands.
Another key project is the launch of an open ampule line at the Alcorcon site, and the investment in a new oral liquid filling line in the Avlonas site, which expands significantly manufacturing capabilities, with focus on operational efficiency and cost-effectiveness, that is for maintaining a competitive edge.
FAMAR’s strategy not only addresses present market needs but also anticipates future trends, reinforcing its commitment to innovation and client satisfaction.
Commitment to ESG and Human Capital Development
Sustainability is a cornerstone of FAMAR’s business strategy, with numerous ESG initiatives aimed at reducing environmental impact. Investments in renewable energy, such as installing photovoltaic systems at its facilities in Greece, Spain, and Italy, have significantly reduced the CO2 emissions. The company has also launched a green investment plan to create photovoltaic parks, targeting a 30% reduction in CO2 emissions by 2030. These efforts not only contribute to environmental stewardship but also enhance FAMAR’s long-term viability, appealing to eco- conscious stakeholders.
FAMAR’s commitment to ESG extends beyond environmental impact, earning recognition for its sustainability initiatives. Human capital development is another cornerstone of FAMAR’s strategy. The company has made significant investments in its workforce, launching programs like the FAMAR SCHOOL in collaboration with Harvard Business School to enhance the professional skills of its employees. This focus on continuous improvement and innovation ensures that FAMAR’s teams are well-equipped to meet the challenges of the dynamic pharmaceutical industry.
As FAMAR celebrates 75 years of innovation and growth, it remains steadfast in its commitment to strategic investment, sustainability, and continuous improvement. FAMAR has received numerous awards for its excellence in the CDMO sector. The company’s ability to consistently deliver high-quality services and innovative solutions has earned it a place among the top CDMO companies globally, as evidenced by its multiple recognitions from organizations like Ecovadis and the CDMO Leadership Awards.
The company’s strategic investments in advanced technologies and sustainable practices position it as a reliable partner in the CDMO industry. FAMAR is well-equipped to continue its legacy of excellence, contributing to the improvement of patient and consumer lives worldwide.
Meet the FAMAR team at CDMO Live. Register today for your free ticket
Stay ahead of trends and best practices
